Fatty-acid metabolism, energy, liver lipid metabolism, exercise recovery
Lipo-C (Fat Blaster)
A concentrated blend of L-carnitine, MIC, B6, B12 and NADH studied for fatty-acid transport, liver lipid metabolism, mitochondrial energy, exercise recovery, and metabolic support.
Administration Reference
Intramuscular
Source / Evidence Context
Commonly reported use — not established guidance
Formulation & Context
Lipo-C Fat Blaster, also referred to as LC526, is a concentrated lipotropic and metabolic-support blend.
Dose Information
0.5–1.0 mL per administration
Frequency
3 times weekly
Duration / Cycle
4–8 weeks, some community and clinic protocols extend to 8–12 weeks
Off-Cycle
Common practice is reducing to once per week. No fixed off-cycle
Timing
Morning or approximately 30–60 minutes before exercise
Storage Guidance
Cool, dark place away from moisture and direct sunlight.
Supplies
Affiliate disclosure: We may earn a commission if you purchase through these links.
Listings are not a required kit or confirmation of suitability for a particular peptide, formulation, or route. Check the product specifications and intended use.
Syringes & transfer supplies
BH Supplies Insulin Syringes U-100 29G 1ml/cc 1/2″ (12.7mm) Pack of 100 Pcs29g 1/2" syringePolybag, 100 Unit Capacity, 1/2” Needle Length, Bold Markings for Accurate Dosing, Disposable, Box of 100View at AMAZON →
Protective supplies & disposal
MED PRIDE Sterile Alcohol Prep Pads1 BOX OF 200INDIVIDUALLY WRAPPED ISOPROPYL ALCOHOL WIPES, PACK OF 1 BOX OF 200, MEDIUM SIZE PREP PADSView at AMAZON →
Inspire Black Nitrile Gloves HEAVY DUTY 6 Mil100ctView at AMAZON →
Square Sharps Container, 2 QuartQTY 1View at AMAZON →
Commonly Reported Uses
Fat-metabolism support; mitochondrial energy production; exercise endurance; pre-workout energy; cardiovascular exercise support; recovery; reduced exercise-related fatigue; calorie-deficit support; liver lipid metabolism; methylation support; B-vitamin supplementation; insulin and glucose metabolism; general metabolic resilience.
Commonly Reported Indicators
Commonly reported observations include increased energy without a strong stimulant effect, improved pre-cardio energy, greater exercise tolerance, less perceived fatigue, improved workout recovery, reduced soreness, and more consistent daytime energy. Some users report benefits within the first several administrations, while body-composition effects are generally assessed over multiple weeks. Community responses vary substantially.
Mechanism Overview
L-carnitine supports transport of long-chain fatty acids into mitochondria for beta-oxidation and energy production. Methionine and choline participate in one-carbon metabolism, methylation, phosphatidylcholine synthesis, and hepatic lipid handling. Inositol participates in intracellular signaling and insulin-related pathways. Vitamin B6 supports more than 100 enzyme reactions involving amino-acid, carbohydrate, and lipid metabolism; B12 supports methionine synthase, DNA synthesis, neurologic function, and fatty-acid metabolism; NADH transfers reducing equivalents into cellular energy-production pathways.
Safety
Safety Considerations
This is a concentrated multi-ingredient formulation, so tolerability should be considered at both the total-volume and individual-ingredient level. Important issues include injection-site irritation, gastrointestinal symptoms, L-carnitine-associated odor or nausea, B12 hypersensitivity, and cumulative vitamin B6 exposure. Repeated high B6 exposure deserves particular attention because chronic excessive pyridoxine exposure can cause progressive sensory neuropathy.
Reported Adverse Effects
Injection-site pain, burning, redness, swelling or welts; nausea; gastrointestinal discomfort; headache; flushing; dizziness; restlessness or increased alertness; fishy body odor associated with carnitine metabolism; and allergic reactions to individual formulation components. Chronic excessive vitamin B6 exposure can produce numbness, tingling, sensory changes, ataxia, or peripheral neuropathy. Community reports specifically describe substantial burning and prolonged local swelling with some subcutaneous LC526 preparations.
Contraindications & Cautions
Known hypersensitivity to any formulation component; significant kidney disease; severe liver disease; seizure disorders or seizure history; pre-existing peripheral neuropathy; substantial supplemental vitamin B6 intake from other products; pregnancy or breastfeeding unless clinically directed; and concurrent therapies where altered nutrient or metabolic exposure may complicate management. NIH notes that high-dose carnitine can cause gastrointestinal effects and may present concern in people with seizure disorders.
Cancer Considerations
Editorial evidence assessment, not a validated risk score or clearance for use. Unknown risk does not mean low risk; these notes do not establish safety during active cancer or remission.
Cancer Concern Assessment
Low theoretical concern
Basis for Concern
LC526 does not directly stimulate GH/IGF-1, VEGF, or telomerase. The theoretical concern is instead metabolic: methionine, fatty-acid oxidation, one-carbon metabolism, mitochondrial redox pathways, and B-vitamin-dependent reactions are also used by malignant cells. These pathways are fundamental to normal physiology and their involvement in tumor metabolism does not demonstrate that LC526 initiates or accelerates cancer.
Active Cancer
Caution due to mechanism
No evidence demonstrates that LC526 promotes human tumor growth. However, supplemental amino acids and metabolic cofactors may interact differently with cancer-cell metabolism or oncology treatments depending on tumor type. High-dose supplementation during chemotherapy or radiation is best considered in the context of the specific treatment strategy.
Prior Cancer / Remission
Individualized caution
No evidence-based remission interval has been established. This formulation lacks the direct proliferative signaling associated with GH-axis or strongly angiogenic compounds, so the theoretical concern is comparatively lower, but unnecessary high-dose metabolic supplementation should still be individualized.
Status
Regulatory Status
Lipo-C Fat Blaster/LC526 is not an FDA-approved drug for obesity, localized fat destruction, exercise enhancement, or weight loss. Lipo-C is a broad formulation category used by wellness clinics, compounding pharmacies, and research suppliers rather than a standardized FDA-approved pharmaceutical product. Fella Health likewise identifies conventional Lipo-C formulations as unapproved compounded products with substantial formulation variability.
Development / Research Status
Research status unclear
Market Classification
Varies by jurisdiction or formulation
Status Notes
For this profile, “Lipo-C Fat Blaster” typically refers to LC526: L-carnitine 300 mg/mL + methionine 25 mg/mL + inositol 50 mg/mL + choline 50 mg/mL + B12 1 mg/mL + B6 50 mg/mL + NADH 50 mg/mL. It should not be conflated with conventional MIC-B12 Lipo-C, other enhanced lipotropic blends, or PCDC/deoxycholate mesotherapy products that are also sometimes marketed using “Lipo C” terminology.
Research & Evidence
Evidence Level
Human clinical research
Research Last Reviewed
2026-09-06
Research Overview
The exact LC526 combination has not been the subject of a controlled clinical trial, but its major ingredients have substantial independent human and mechanistic literature. The strongest body-composition evidence involves L-carnitine, while inositol has metabolic and insulin-sensitivity research. Choline, methionine, B6, B12, and NADH have established roles in hepatic lipid handling, one-carbon metabolism, mitochondrial energy production, and cellular metabolism. The evidence is therefore best characterized as human clinical research at the component level, rather than clinical validation of the proprietary combination.
Human Research
L-carnitine has the most directly relevant weight-management evidence. A meta-analysis of 37 randomized controlled trials involving 2,292 participants found modest reductions in body weight, BMI, and fat mass with L-carnitine supplementation. Mean weight reduction versus controls was approximately 1.21 kg and fat-mass reduction approximately 2.08 kg. The studies primarily involved oral supplementation and therefore do not directly establish equivalent effects from 300 mg injectable L-carnitine in LC526.
Inositol has substantial human metabolic research. A meta-analysis of 20 randomized controlled trials involving 1,239 participants found improvements in fasting glucose, fasting insulin, glucose tolerance, and HOMA-IR. These findings support the ingredient’s role in insulin-related metabolic signaling but do not demonstrate that injectable LC526 produces the same outcomes.
Vitamin B6 has extensive human biochemical and clinical data involving protein, carbohydrate, lipid, neurotransmitter, immune, and homocysteine metabolism. Vitamin B12 is essential to methionine synthase activity, DNA synthesis, neurologic function, red-blood-cell production, and methylmalonyl-CoA metabolism. The 1 mg B12 quantity in a full 1 mL LC526 dose is substantially above ordinary nutritional requirements and is more comparable to pharmacologic B12 replacement quantities than dietary supplementation.
NADH has been studied in small human fatigue trials. In a randomized double-blind crossover study of 26 patients with chronic fatigue syndrome, 10 mg oral NADH produced a favorable response in 31% of participants compared with 8% receiving placebo. LC526 contains 50 mg NADH per mL, but route and formulation differences prevent direct extrapolation of that study to injectable LC526.
Animal Research
Animal and nutritional research helped establish the biochemical rationale behind “lipotropic” formulations. Methionine and choline availability strongly influence hepatic phospholipid synthesis, methyl-group metabolism, lipid export, and accumulation of liver fat. L-carnitine is essential to mitochondrial transport and oxidation of long-chain fatty acids. These pathways provide a rational basis for studying the ingredients together, although they do not establish pharmacologic fat loss from LC526 itself.
In Vitro Research
At the cellular level, the components target complementary metabolic pathways. L-carnitine participates in the mitochondrial carnitine shuttle; methionine supplies S-adenosylmethionine for methylation reactions; choline supports phosphatidylcholine synthesis and lipid transport; inositol derivatives participate in intracellular signaling; pyridoxal phosphate acts as a coenzyme in amino-acid and macronutrient metabolism; B12 supports methionine synthase and methylmalonyl-CoA mutase; and NADH supplies reducing equivalents used in cellular ATP production.
References
Talenezhad N, Mohammadi M, Ramezani-Jolfaie N, et al. Effects of L-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis. Clin Nutr ESPEN. 2020;37:9-23. PMID 32359762. DOI 10.1016/j.clnesp.2020.03.008.
Miñambres I, Cuixart G, Gonçalves A, Corcoy R. Effects of inositol on glucose homeostasis: systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2019;38(3):1146-1152. PMID 29980312. DOI 10.1016/j.clnu.2018.06.957.
Forsyth LM, Preuss HG, MacDowell AL, et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol. 1999;82(2):185-191. PMID 10071523. DOI 10.1016/S1081-1206(10)62595-1.
National Institutes of Health, Office of Dietary Supplements. Carnitine — Health Professional Fact Sheet.
National Institutes of Health, Office of Dietary Supplements. Vitamin B6 — Health Professional Fact Sheet.
National Institutes of Health, Office of Dietary Supplements. Vitamin B12 — Health Professional Fact Sheet.
National Institutes of Health, Office of Dietary Supplements. Choline — Health Professional Fact Sheet.
Mato JM, Martínez-Chantar ML, Lu SC. Methionine metabolism and liver disease. Annu Rev Nutr. 2008;28:273-293. DOI 10.1146/annurev.nutr.28.061807.155438.
One-Carbon Metabolism in Fatty Liver Disease and Fibrosis: One-Carbon to Rule Them All. J Nutr. 2020. PMID 32119738. DOI 10.1093/jn/nxaa032.
Fella Health. Lipo C and Tirzepatide: Safety and Clinical Evidence Review. Review of conventional MIC-B12 formulation, formulation variability, administration and safety considerations.
LC526 Lipo-C Fat Blaster. Current formulation and community protocol reference: 526 mg/mL total active ingredients.
Plastic Surgery Specialists. Lipo C Injections. Used only to distinguish PCDC/phosphatidylcholine-deoxycholate mesotherapy from the LC526 metabolic blend represented on this profile.